Summary

Overview
Global Avian influenza Treatment Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing with a CAGR of XX % during the forecast period 2024-2031.
Avian influenza, commonly known as bird flu, is a viral infection that primarily affects birds, including domestic poultry and wild birds. There are several strains of avian influenza viruses, with some causing mild illness and others being highly pathogenic and capable of causing severe disease and death in birds. Avian influenza viruses have the potential to mutate and acquire the ability to spread efficiently among humans, leading to a global pandemic.
Developing effective treatments can be crucial in managing such a scenario by reducing the severity of illness, slowing transmission, and saving lives until vaccines can be developed and distributed on a large scale. Investing in avian influenza treatment research fosters innovation and advances scientific understanding of the virus, its transmission dynamics, and potential therapeutic targets.
Market Dynamics: Drivers and Restraints
Rising the prevalence of Avian influenza
The higher prevalence of avian influenza outbreaks can lead to increased demand for treatments. As the number of cases rises, there is greater urgency to develop and distribute effective treatments to control the spread of the virus in both poultry populations and potentially in humans.
Higher prevalence of avian influenza outbreaks may result in increased funding for research into treatment options. Governments, international organizations, and philanthropic entities may allocate more resources to support research and development efforts aimed at finding effective treatments for avian influenza. Thus rise of avian influenza cases helps to accelerates the market growth.
For instance, according to World Health Organization, from 2003 to 25 March 2024, a total of 888 worldwide human cases of infection of influenza A(H5N1), including 463 deaths, have been reported to WHO from 23 countries. Almost all cases of human infection with avian influenza A(H5N1) have been linked to close contact with infected live or dead birds, or contaminated environments. Since 2003, 129 human infections with influenza A (H5N1), including 65 deaths, have been reported in Viet Nam. The most recent avian influenza A (H5) case was reported in October 2022 from Northern Province of Viet Nam.
Market Dynamics: Restraint
Limited awareness about avian influenza
Lack of awareness about avian influenza and its potential impact on human and animal health may result in low demand for treatments. Public education campaigns and outreach efforts may be needed to raise awareness about the importance of avian influenza treatment and prevention measures. If the general public lacks awareness of avian influenza and its potential impact on human health, there may be reduced demand for treatments.
Individuals may not seek medical attention promptly or may underestimate the severity of symptoms, leading to delayed diagnosis and treatment initiation. Lack of awareness about avian influenza may result in underutilization of healthcare services, particularly in regions where the disease is less prevalent or perceived as a low priority health concern. This can lead to missed opportunities for early diagnosis, treatment, and prevention of avian influenza.
For more details of the report, Request for sample
Segment Analysis
The global avian influenza treatment market is segmented based on drug type, flu strain, distribution channel and region.
The antibiotics from the drug type segment accounted for approximately 41.09% of share
While avian influenza itself is caused by viruses, affected birds may be prone to secondary bacterial infections due to the weakening of their immune systems. In such cases, antibiotics may be used to treat bacterial complications rather than the primary viral infection. Given the limited role of antibiotics in treating avian influenza, research and development efforts in the poultry industry and veterinary medicine sector often prioritize vaccines, antiviral drugs, and other non-antibiotic interventions for disease control and prevention.
Fir instance, according to WHO 2023, the patient was admitted to the intensive care unit and treatment with antivirals (oseltamivir) and antibiotics was initiated. The patient remains in respiratory isolation under multidisciplinary management, with mechanical ventilation due to pneumonia.
Overall, while antibiotics may have a limited role in the treatment of avian influenza, their use is primarily focused on managing secondary bacterial infections rather than directly targeting the primary viral infection. The rise of the antibiotics segment in the avian influenza treatment market is therefore constrained by the viral nature of the disease and the broader emphasis on preventive measures and alternatives to antibiotic use in poultry farming.
Geographical Analysis
North America accounted for approximately 39.04% of the market share in 2023
North America is a hub for pharmaceutical and biotechnology companies engaged in research and development of avian influenza treatments. Investment in innovative technologies, drug discovery platforms, and vaccine development accelerates the introduction of new and improved treatments to the market, driving growth opportunities.
Additionally, North America has a significant poultry industry, with high levels of poultry consumption and production. For instance, according to the USDA, the average U.S. resident consumes 224.6 pounds of meat beef, pork, broilers and turkey every year. Meat consumption in the United States reached record highs in 2021, and, though the following year saw a slight downtick, 2022 reached similar levels as the second-highest year on record.
Moreover, North America is a major player in international trade, including the import and export of poultry products. Compliance with international health and safety standards, including measures to control avian influenza, is essential for maintaining market access and competitiveness. This drives demand for avian influenza treatments and supports market growth.
COVID-19 Impact Analysis
In late 2019, the novel coronavirus disease (COVID‐19) broke out and swept the world population. Drastic mitigation measures were implemented among the international community to stop the COVID‐19 crisis, including mass quarantine, physical distancing, and face mask usage. However, the elevated trend of human infections with the emerging AIV during ongoing COVID‐19 circulation still highlights the alert of the possible risk for the next human pandemic.
Under the current challenge of the COVID‐19 pandemic, strict control practices were carried out to curb this fulminating disease with a substantial decrease in global seasonal influenza transmission. Due to limited laboratory testing capacities and medical resources, human cases infected with AIV may be ignored. However, the frequent outbreaks of AIV in poultry and wild birds and the rapid rise in human infections should remind us to monitor and prepare for the latent risk of a disastrous pandemic.
Market Segmentation
By Drug Type
• Antibiotics
• Vaccines
• Antiviral Agents
• Immunoglobulins
By Flu Strain
• H5N1
• H7N9
• H9N
• Others
By Distribution Channel
• Online Pharmacies
• Offline Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include F. Hoffmann-La Roche Ltd, Shionogi & Co., Ltd., GlaxoSmithKline, BioCryst Pharmaceuticals, Gilead Sciences, Sanofi, Cipla, Pfizer, Sinovac Biotech, Teva Pharmaceuticals among others.
Why Purchase the Report?
• To visualize the global avian influenza treatment market segmentation based on drug type, flu strain, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of avian influenza treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global avian influenza treatment market report would provide approximately 69 tables, 58 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Flu Strain
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising the prevalence of avian influenza
4.1.1.2. Increasing the advances in immunology, and drug discovery techniques
4.2. Restraints
4.2.1.1. Limited awareness about avian influenza
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Antibiotics *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Vaccines
7.4. Antiviral Agents
7.5. Immunoglobulins
8. By Flu Strain
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Flu Strain
8.1.2. Market Attractiveness Index, By Flu Strain
8.2. H5N1 *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. H7N9
8.4. H9N
8.5. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Online Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Offline Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Flu Strain
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Flu Strain
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Flu Strain
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Flu Strain
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Flu Strain
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. F. Hoffmann-La Roche Ltd *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Shionogi & Co., Ltd.
12.3. GlaxoSmithKline
12.4. BioCryst Pharmaceuticals
12.5. Gilead Sciences
12.6. Sanofi
12.7. Cipla
12.8. Pfizer
12.9. Sinovac Biotech
12.10. Teva Pharmaceuticals
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us